


XENITH•UC

Global Phase 2 Trial Launching Soon

Anti-TL1A



High
Potency

Extended
Half-Life

XmAb942

XmAb942 (anti-TL1A)¹

Potentially differentiated
therapeutic profile in IBD^{2,3}

Phase 2 portion of
seamless Phase 1/2 trial
initiating in 2025

Phase 1 interim data support
development in ulcerative colitis
and Crohn's disease

**Learn more about XENITH-UC
Booth #5358**

1. XmAb942 is an investigational anti-TL1A antibody in development for patients with inflammatory bowel disease, such as ulcerative colitis (UC) and Crohn's disease (CD).
2. Hung K, et al. *Journal of Crohn's and Colitis*, Volume 19, Issue Supplement_1, January 2025, Page i2015 (Poster P1097).
3. Ernst JA, et al. *UEG J.* 2025;12: 554 (Poster MP568).

